

ASX MEDIA RELEASE

30 September 2022

Date of Annual General Meeting – 24 November 2022

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer is pleased to announce, in accordance with Listing Rule 3.13.1, that the date of its AGM will be Thursday 24 November 2022.

In accordance with Clarity’s Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a Director is 7 October 2022.

Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting, which will be sent to shareholders. The Notice of Meeting will also be available on the ASX Company Announcements Platform and the Company’s website.

This announcement has been authorised for release by Dr Alan Taylor, Executive Chairman.

For more information, please contact:

Dr Alan Taylor
Executive Chairman
Clarity Pharmaceuticals
ataylor@claritypharm.com

Catherine Strong
Investor/Media Relations
Citadel-MAGNUS
cstrong@citadelmagnus.com
+61 406 759 268

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

www.claritypharmaceuticals.com/